Q&A: George Church on Genomics of Cognitive Enhancement
Bill of Health
JUNE 12, 2024
The practicality I’ve noticed over the years is that no matter what we aim at, there’s the very severe, shorter-term FDA trial. In 2014 CRISPR gene drives. GC: It has piqued my interest for many years. If you look at gene therapies, I’ve been kind of a vocal opponent and advocate of gene therapies for rare diseases.
240 
Let's personalize your content